Genextra
Financials
Estimates*
EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|---|
EBITDA | (1.7m) | (2.4m) | (1.5m) | (1.9m) | (1.7m) | (1.8m) | (1.5m) |
Profit | (5.4m) | (6.9m) | 1.4m | 32.4m | (5.7m) | 93.1m | (<1m) |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
Total Funding | - |
Related Content
Recent News about Genextra
EditGenextra is a privately owned holding company specializing in investments in early-stage life science companies. Founded in 2004 and based in Italy, Genextra focuses on identifying innovative research in the life sciences sector and advancing novel therapies and tools through strategic business initiatives. The company operates without territorial limits but benefits from preferential access to high-quality Italian-based science. Genextra's business model involves seeking and fostering life sciences investment opportunities, as well as building the necessary infrastructure and management teams to facilitate growth. The company generates revenue through equity investments in promising startups and early-stage companies, aiming to create value for its shareholders. Genextra serves a diverse range of clients, including researchers, entrepreneurs, and other stakeholders in the life sciences ecosystem.
Keywords: life sciences, early-stage investments, innovative therapies, holding company, Italian-based science, strategic initiatives, infrastructure development, management support, equity investments, shareholder value.